Oculis Holding Ag (OCS) Stock Price, Quote & News

Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease m...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 41 711 3960

Website: oculis.com

Address:

Bahnhofstrasse 20, Zug, Switzerland

justiceforb_85 Jul. 2 at 11:10 PM

$OCS recovering nicely. Dry eye candidate not as exciting as privosegtor for ON, the latter with significant preliminary efficacy data and a niche drug.

0 · Reply

VeltrixCapitalOfficial Jul. 2 at 3:56 PM

High Confidence 🚨 $OCS 15 Call 7/17 at 0.65

0 · Reply

ApexEquityVault Jul. 2 at 3:47 PM

$OCS 15 Call 7/17 at 0.65

0 · Reply

chartistmind Jun. 30 at 7:58 PM

$OCS it is official, another 20%+ 🚀 ripper within just days memorialized into the stocktits records.

0 · Reply

crabbypatty31 Jun. 30 at 4:12 PM

$OCS Happily, this has been a great trade after the fall. Holding a nice position from here forward:))

0 · Reply

chartistmind Jun. 29 at 9:20 PM

$OCS fam, it’s done. We got another 10%+ 🐌 🚀 ripper within weeks on this garbage.

0 · Reply

G101SPM Jun. 25 at 7:39 PM

#SHOWTIME European Academy of Neurology Congress (June 26) Scheduled to appear: $IMUX, $OCS United Therapeutics Corporation Annual General Meeting (June 26) Scheduled to appear: $UTHR Aon Plc Class A Annual General Meeting (June 26) Scheduled to appear: $AON

0 · Reply

Messerschmittbf109 Jun. 24 at 6:19 PM

$OCS I’ll re wait for 4$

0 · Reply

Champi2305 Jun. 17 at 5:23 PM

$OCS https://investors.oculis.com/news-releases/news-release-details/oculis-publishes-notifications-transactions-persons-32/

0 · Reply

StreetwiseReports Jun. 16 at 4:03 PM

Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment https://ow.ly/rWFm50ZcntE Oculis Holding AG launches the PREDICT-1 trial for licaminlimab, targeting patients with a specific TNFR1 genotype to address unmet needs in the large dry eye disease market. $OCS

0 · Reply

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

Jun 11, 2026, 4:00 AM EDT - 23 days ago

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026

Jun 10, 2026, 4:05 PM EDT - 23 days ago

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Jun 9, 2026, 4:00 PM EDT - 24 days ago

Oculis Holding AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 4:00 AM EDT - 25 days ago

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease

Jun 8, 2026, 2:45 PM EDT - 26 days ago

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference

Jun 4, 2026, 7:00 AM EDT - 4 weeks ago

Oculis Holding AG Slides: Study update presentation

2026-06-03T15:35:08.000Z - 4 weeks ago

Oculis price target lowered to $23 from $42 at JPMorgan

Jun 2, 2026, 11:23 AM EDT - 4 weeks ago

Oculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

2026-06-02T11:27:11.000Z - 4 weeks ago

Oculis price target lowered to $38 from $49 at Baird

2026-06-01T18:15:08.000Z - 4 weeks ago

Oculis price target lowered to $38 from $49 at Baird

2026-06-01T13:51:59.000Z - 4 weeks ago

Oculis price target lowered to $35 from $44 at BofA

2026-06-01T11:49:15.000Z - 4 weeks ago

Oculis price target lowered to $38 from $46 at Needham

2026-06-01T11:48:24.000Z - 4 weeks ago

Oculis price target lowered to $45 from $75 at Guggenheim

2026-06-01T11:02:22.000Z - 4 weeks ago

Oculis price target lowered to $26 from $47 at H.C. Wainwright

2026-06-01T10:54:52.000Z - 4 weeks ago

Oculis price target lowered to $40 from $50 at Stifel

May 29, 2026, 4:30 PM EDT - 5 weeks ago

Oculis Holding AG Transcript: Study result

May 29, 2026, 4:30 PM EDT - 5 weeks ago

Oculis Holding AG Press release: Study result

May 29, 2026, 4:30 PM EDT - 5 weeks ago

Oculis Holding AG Slides: Study result

2026-05-29T20:25:49.000Z - 5 weeks ago

Oculis Holding AG trading resumes

May 29, 2026, 3:06 PM EDT - 5 weeks ago

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

2026-05-29T19:01:51.000Z - 5 weeks ago

Oculis reports primary endpoint of DIAMOND Phase 3 trials was not met

2026-05-29T18:45:54.000Z - 5 weeks ago

Oculis Holding AG trading halted, news pending

2026-05-29T18:30:13.000Z - 5 weeks ago

Oculis quickly falls 26% to $22 per share

2026-05-20T20:15:09.000Z - 6 weeks ago

Oculis initiated with a Buy at Guggenheim

2026-05-18T11:45:55.000Z - 6 weeks ago

Oculis price target raised to $42 from $38 at JPMorgan

May 14, 2026, 4:05 PM EDT - 7 weeks ago

Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors

May 13, 2026, 6:00 AM EDT - 7 weeks ago

Oculis Holding AG Transcript: AGM 2026

May 13, 2026, 6:00 AM EDT - 7 weeks ago

Oculis Holding AG Slides: FY 2026

2026-05-12T17:40:18.000Z - 7 weeks ago

Oculis price target raised to $47 from $44 at H.C. Wainwright

2026-05-12T14:11:25.000Z - 7 weeks ago

Oculis price target raised to $44 from $43 at BofA

2026-05-11T23:11:34.000Z - 7 weeks ago

Oculis reports Q1 EPS (49c), consensus (41c)

May 11, 2026, 4:05 PM EDT - 7 weeks ago

Oculis Reports Q1 2026 Financial Results and Provides Company Update

May 11, 2026, 1:00 AM EDT - 7 weeks ago

Oculis Holding AG Earnings release: Q1 2026

May 7, 2026, 4:57 AM EDT - 2 months ago

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

May 5, 2026, 4:00 AM EDT - 2 months ago

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

May 1, 2026, 4:00 AM EDT - 2 months ago

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Apr 21, 2026, 4:05 PM EDT - 2 months ago

Oculis Publishes Invitation to the Annual General Meeting

Apr 20, 2026, 4:00 AM EDT - 2 months ago

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Apr 14, 2026, 9:30 AM EDT - 2 months ago

Oculis Holding AG Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 4:00 AM EDT - 3 months ago

Oculis to Participate in Upcoming Investor Conferences

Mar 31, 2026, 5:00 AM EDT - 3 months ago

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

Mar 16, 2026, 5:00 AM EDT - 3 months ago

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

Mar 10, 2026, 10:40 AM EDT - 4 months ago

Oculis Holding AG Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 4:00 AM EST - 4 months ago

Oculis Publishes 2025 Consolidated Financial Statements

Mar 3, 2026, 4:05 PM EST - 4 months ago

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update

Mar 3, 2026, 4:00 PM EST - 4 months ago

Oculis Holding AG Annual report: Q4 2025

Mar 3, 2026, 4:00 PM EST - 4 months ago

Oculis Holding AG Earnings release: Q4 2025

Mar 3, 2026, 4:00 PM EST - 4 months ago

Oculis Holding AG Annual report: Q4 2025

Feb 18, 2026, 4:05 PM EST - 4 months ago

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated

Feb 17, 2026, 4:00 AM EST - 4 months ago

Oculis Appoints Katie Kazem as Chief Legal Officer

Jan 14, 2026, 4:30 PM EST - 6 months ago

Oculis Holding AG Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 6 months ago

Oculis Holding AG Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:00 AM EST - 6 months ago

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

Jan 6, 2026, 4:00 AM EST - 6 months ago

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

Nov 12, 2025, 2:00 PM EST - 8 months ago

Oculis Holding AG Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 12:30 PM EST - 8 months ago

Oculis Holding AG Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 4:05 PM EST - 8 months ago

Oculis Reports Q3 2025 Financial Results and Provides Company Update

Nov 10, 2025, 4:00 PM EST - 8 months ago

Oculis Holding AG Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

Oculis Holding AG Registration statement: Registration Filing

Nov 5, 2025, 4:00 AM EST - 8 months ago

Oculis to Participate in Upcoming November Investor Conferences

Oct 30, 2025, 4:30 AM EDT - 8 months ago

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development

Oct 14, 2025, 4:00 AM EDT - 9 months ago

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

Oct 6, 2025, 8:30 AM EDT - 9 months ago

Oculis Holding AG Transcript: Status Update

Oct 6, 2025, 8:30 AM EDT - 9 months ago

Oculis Holding AG Press release: Status Update

Oct 6, 2025, 8:30 AM EDT - 9 months ago

Oculis Holding AG Slides: Status Update

Oct 6, 2025, 4:07 AM EDT - 9 months ago

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Sep 26, 2025, 4:05 PM EDT - 10 months ago

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

Sep 22, 2025, 4:00 AM EDT - 10 months ago

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

Sep 9, 2025, 3:45 PM EDT - 10 months ago

Oculis Holding AG Transcript: Baird Global Healthcare Conference 2025

Sep 8, 2025, 2:30 PM EDT - 10 months ago

Oculis Holding AG Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 1:00 PM EDT - 10 months ago

Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025

Sep 1, 2025, 4:00 AM EDT - 10 months ago

Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Aug 28, 2025, 4:00 AM EDT - 11 months ago

Oculis to Participate in Upcoming September Investor Conferences

Aug 25, 2025, 4:00 AM EDT - 11 months ago

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

Aug 21, 2025, 4:05 PM EDT - 11 months ago

Oculis Reports Q2 2025 Financial Results and Provides Company Update

Aug 21, 2025, 4:00 PM EDT - 11 months ago

Oculis Holding AG Earnings release: Q2 2025

Aug 13, 2025, 11:00 AM EDT - 11 months ago

Oculis Holding AG Transcript: Fireside Chat

Aug 13, 2025, 7:00 AM EDT - 11 months ago

Oculis Holding AG Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 12, 2025, 4:00 AM EDT - 11 months ago

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 12, 2025, 4:00 AM EDT - 11 months ago

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 1, 2025, 4:00 AM EDT - 1 year ago

Oculis Upsized Loan Facility to Access up to CHF 100 million

Jun 5, 2025, 4:00 AM EDT - 1 year ago

Oculis Publishes Results of 2025 Annual General Meeting

Jun 3, 2025, 4:00 AM EDT - 1 year ago

Oculis to Participate in Upcoming June Investor Conferences

May 27, 2025, 1:00 PM EDT - 1 year ago

Oculis Holding AG Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 20, 2025, 9:30 AM EDT - 1 year ago

Oculis Holding AG Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 14, 2025, 6:00 PM EDT - 1 year ago

Oculis Holding AG Transcript: BofA Securities 2025 Healthcare Conference

May 8, 2025, 4:05 PM EDT - 1 year ago

Oculis Reports Q1 2025 Financial Results and Provides Company Update

justiceforb_85 Jul. 2 at 11:10 PM

$OCS recovering nicely. Dry eye candidate not as exciting as privosegtor for ON, the latter with significant preliminary efficacy data and a niche drug.

0 · Reply

VeltrixCapitalOfficial Jul. 2 at 3:56 PM

High Confidence 🚨 $OCS 15 Call 7/17 at 0.65

0 · Reply

ApexEquityVault Jul. 2 at 3:47 PM

$OCS 15 Call 7/17 at 0.65

0 · Reply

chartistmind Jun. 30 at 7:58 PM

$OCS it is official, another 20%+ 🚀 ripper within just days memorialized into the stocktits records.

0 · Reply

crabbypatty31 Jun. 30 at 4:12 PM

$OCS Happily, this has been a great trade after the fall. Holding a nice position from here forward:))

0 · Reply

chartistmind Jun. 29 at 9:20 PM

$OCS fam, it’s done. We got another 10%+ 🐌 🚀 ripper within weeks on this garbage.

0 · Reply

G101SPM Jun. 25 at 7:39 PM

0 · Reply

Messerschmittbf109 Jun. 24 at 6:19 PM

$OCS I’ll re wait for 4$

0 · Reply

Champi2305 Jun. 17 at 5:23 PM

$OCS https://investors.oculis.com/news-releases/news-release-details/oculis-publishes-notifications-transactions-persons-32/

0 · Reply

StreetwiseReports Jun. 16 at 4:03 PM

0 · Reply

StreetwiseReports Jun. 15 at 4:08 PM

Biopharma Co. Trials Precision Medicine Breakthrough for Dry Eye Disease. Gets Positive Results https://ow.ly/7AEF50ZbUXu Oculis Holding AG ( $OCS ) launches PREDICT-1, a genotype-based trial for licaminlimab, targeting 10M moderate-to-severe dry eye patients.

0 · Reply

justiceforb_85 Jun. 12 at 11:02 PM

$OCS feel like company should focus on privosegtor in ON. Not as confident on their dry eye asset.

0 · Reply

ClassiTrader Jun. 10 at 4:49 PM

$OCS 👀🃏

0 · Reply

JohnnySecretz Jun. 9 at 6:08 PM

$OCS $9.20 then ded cat to $13

0 · Reply

Merlintrader Jun. 9 at 10:15 AM

$OCS Oculis Holding AG (Nasdaq: $OCS): PREDICT-1 Starts as Licaminlimab Becomes the Next Test After the DIAMOND Phase 3 Miss https://www.merlintrader.com/oculis-holding-predict/

1 · Reply

LetsgoDudeszi Jun. 8 at 4:36 PM

$OCS still dumping strong! would not toouch this even at 5$

0 · Reply

Messerschmittbf109 Jun. 5 at 7:38 PM

$OCS scam

0 · Reply

Merlintrader Jun. 5 at 12:02 PM

$OCS Oculis Holding AG (Nasdaq: $OCS): DIAMOND Phase 3 miss resets the story toward Privosegtor and Licaminlimab https://www.merlintrader.com/oculis-holding-ag-diamond-phase-3-miss/

0 · Reply

Messerschmittbf109 Jun. 4 at 7:24 PM

$OCS you right .. but I have see the book all day But…These are “ mariuoli” scoun & dr ..& ls Mm , insiders , houses of affairs? I don’t know but….

0 · Reply

FetchDog Jun. 4 at 6:33 PM

$OCS Wait for this to drop for approximately 10 days in sequence before buying the dip. That means 6 more trading days, or around June 12. That's a pattern I've noticed for buying stocks that have been hit hard without near term catalysts. If you buy this, plan to hold for 1+ years for your reward.

0 · Reply

Messerschmittbf109 Jun. 4 at 6:21 PM

$OCS tuna slaughter festival

0 · Reply

Messerschmittbf109 Jun. 4 at 5:47 PM

$OCS dear Bro pay attention these scou n @DrElswhere are professionals It seems a fart vacuum stock

0 · Reply

Market Cap	818.73M
Revenue (ttm)	1.45M
Net Income (ttm)	-119.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-8,237.24%
Debt to Equity Ratio	0.00

Volume	398,400
Avg Vol	807,142
Day's Range	N/A - N/A
Shares Out	57.98M
Stochastic %K	93%
Beta	0.44
Analysts	Strong Sell
Price Target	$39.82